Jeffrey Yordon - Aug 3, 2021 Form 4 Insider Report for Athenex, Inc. (ATNXQ)

Role
COO, and President, Athenex Pharmaceutical Division.
Signature
/s/ Teresa Bair, Attorney-in-Fact
Stock symbol
ATNXQ
Transactions as of
Aug 3, 2021
Transactions value $
$0
Form type
4
Date filed
8/5/2021, 04:49 PM
Next filing
Jul 21, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ATNXQ Common Stock 237K Aug 3, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATNXQ Stock Option (Right to Buy) Award $0 +50K $0.00 50K Aug 3, 2021 Common Stock 50K $3.80 Direct F3
transaction ATNXQ Restricted Stock Units Award $0 +50K $0.00 50K Aug 3, 2021 Common Stock 50K Direct F4, F5
holding ATNXQ Stock Option (Right to Buy) 150K Aug 3, 2021 Common Stock 150K $9.00 Direct
holding ATNXQ Stock Option (Right to Buy) 212K Aug 3, 2021 Common Stock 212K $11.00 Direct
holding ATNXQ Stock Option (Right to Buy) 100K Aug 3, 2021 Common Stock 100K $17.30 Direct F1
holding ATNXQ Stock Option (Right to Buy) 100K Aug 3, 2021 Common Stock 100K $13.17 Direct F2
holding ATNXQ Stock Option (Right to Buy) 100K Aug 3, 2021 Common Stock 100K $12.45 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vests in four equal annual installments beginning on March 27, 2019.
F2 This option vests in four equal annual installments beginning on February 28, 2020.
F3 This option vests in four equal annual installments beginning on August 3, 2022.
F4 Each restricted stock unit represents a contingent right to receive one share of stock.
F5 The restricted stock units vest in four equal annual installments beginning on August 3, 2022.

Remarks:

COO, and President, Athenex Pharmaceutical Division.